Navigation Links
Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012
Date:3/15/2012

WELWYN GARDEN CITY, England and BOSTON, March 15, 2012 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Business Officer, Barry Kenny, will present overview of the Company at 09:45am CET on Tuesday 20 March 2012 at the 6th Annual BIO-Europe Spring international partnering conference. The presentation will take place in room E107, Level 1.

BIO-Europe Spring, which is produced by EBD Group, is taking place at the Amsterdam RAI Convention Center in Amsterdam, the Netherlands on 19-21 March 2012.

 

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases.  We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures.  Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically un-druggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, anxiety, chronic insomnia, addiction and diabetes.  For more information, please visit http://www.heptares.com.

Contact Information

Citigate Dewe Rogerson
Mark Swallow, Chris Gardner
+44(0)20-7282-2948
mark.swallow@citigatedr.co.uk

Heptares Therapeutics Ltd

Malcolm Weir, Chief Executive Officer (UK)
+44(0)1707-358-629
Malcolm.weir@heptares.com

Dan Grau, President (USA)
+1-857-222-4586
dan.grau@heptares.com


'/>"/>
SOURCE Heptares Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... This report provides all the information you ... and activities since 2010. Download the full ... Deals and Alliance since 2010 report provides an in-depth ... world,s leading life sciences companies. On demand ... of the most up to date deal and company ...
(Date:2/28/2017)... -- Nordic Nanovector ASA (OSE: NANO) announces its results ... the results by the company,s senior management team will take place ... - details below. ... 2016 was a very successful year for Nordic Nanovector. We achieved ... with our preclinical candidates and build the foundation of R&D innovation ...
(Date:2/28/2017)... ... Research and Markets has announced the addition of the "Orthobiologics ... The global orthobiologics market is expected to reach USD 10.2 ... predominantly driven by the increasing orthopedic disease and musculoskeletal disease burden ... of orthobiologics are presumed to accelerate the market demand over the ...
Breaking Medicine Technology:
(Date:2/28/2017)... (PRWEB) , ... February 28, 2017 , ... Las Vegas ... revamped South Rancho location on Friday, March 10, 2017, 4-7 pm PST. For more ... but this clinic, located in the South Rancho neighborhood, has been renovated to provide ...
(Date:2/28/2017)... ... 28, 2017 , ... The role of females in the ... to civilian life. Body image dissatisfaction is largely unexamined among female veterans, a ... occurrence of chronic mental health conditions than female civilians. Female veterans also are ...
(Date:2/27/2017)... ... 27, 2017 , ... Hotze Health & Wellness Center (HHWC), ... its New Guest Director. , Brandl is a dynamic and influential executive ... began his professional career at Omnium Worldwide, now known as West Corporation, and ...
(Date:2/27/2017)... Nashville, TN (PRWEB) , ... February 27, 2017 , ... ... Dot Clayton went to work for a company involved in the underground testing of ... , In “Dying for Answers: Expendable Workers of the Cold War Nuclear Testing,” Clayton ...
(Date:2/27/2017)... ... February 26, 2017 , ... Miro is the ultimate ... and video system brings songs, movies, TV shows and much more apps for user ... high-definition sound. An immersive view of 1280 x 720 provides crisp images with remarkable ...
Breaking Medicine News(10 mins):